Literature DB >> 30344343

Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases.

Diana M Negoescu1, Kostas Bimpikis2, Margaret L Brandeau3, Dan A Iancu2.   

Abstract

Currently available medication for treating many chronic diseases is often effective only for a subgroup of patients, and biomarkers accurately assessing whether an individual belongs to this subgroup typically do not exist. In such settings, physicians learn about the effectiveness of a drug primarily through experimentation, i.e., by initiating treatment and monitoring the patient's response. Precise guidelines for discontinuing treatment are often lacking or left entirely to the physician's discretion. We introduce a framework for developing adaptive, personalized treatments for such chronic diseases. Our model is based on a continuous-time, multi-armed bandit setting where drug effectiveness is assessed by aggregating information from several channels: by continuously monitoring the state of the patient, but also by (not) observing the occurrence of particular infrequent health events, such as relapses or disease flare-ups. Recognizing that the timing and severity of such events provides critical information for treatment decisions is a key point of departure in our framework compared with typical (bandit) models used in healthcare. We show that the model can be analyzed in closed form for several settings of interest, resulting in optimal policies that are intuitive and may have practical appeal. We illustrate the effectiveness of the methodology by developing a set of efficient treatment policies for multiple sclerosis, which we then use to benchmark several existing treatment guidelines.

Entities:  

Year:  2017        PMID: 30344343      PMCID: PMC6193506          DOI: 10.1287/mnsc.2017.2793

Source DB:  PubMed          Journal:  Manage Sci        ISSN: 0025-1909            Impact factor:   4.883


  32 in total

1.  An experimental design for the development of adaptive treatment strategies.

Authors:  S A Murphy
Journal:  Stat Med       Date:  2005-05-30       Impact factor: 2.373

2.  Customizing treatment to the patient: adaptive treatment strategies.

Authors:  Susan A Murphy; L M Collins; A John Rush
Journal:  Drug Alcohol Depend       Date:  2007-03-09       Impact factor: 4.492

3.  Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.

Authors:  K Noyes; A Bajorska; A Chappel; S R Schwid; L R Mehta; B Weinstock-Guttman; R G Holloway; A W Dick
Journal:  Neurology       Date:  2011-07-20       Impact factor: 9.910

4.  Designing a pilot sequential multiple assignment randomized trial for developing an adaptive treatment strategy.

Authors:  Daniel Almirall; Scott N Compton; Meredith Gunlicks-Stoessel; Naihua Duan; Susan A Murphy
Journal:  Stat Med       Date:  2012-03-22       Impact factor: 2.373

5.  The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Authors:  Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

6.  Optimizing the start time of statin therapy for patients with diabetes.

Authors:  Brian T Denton; Murat Kurt; Nilay D Shah; Sandra C Bryant; Steven A Smith
Journal:  Med Decis Making       Date:  2009-05-08       Impact factor: 2.583

7.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

8.  Patient and community preferences for treatments and health states in multiple sclerosis.

Authors:  Lisa A Prosser; Karen M Kuntz; Amit Bar-Or; Milton C Weinstein
Journal:  Mult Scler       Date:  2003-06       Impact factor: 6.312

9.  Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.

Authors:  Soyon Lee; Daniel C Baxter; Brendan Limone; Matthew S Roberts; Craig I Coleman
Journal:  J Med Econ       Date:  2012-05-24       Impact factor: 2.448

Review 10.  Personalized medicine in multiple sclerosis: hope or reality?

Authors:  Tobias Derfuss
Journal:  BMC Med       Date:  2012-10-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.